Search results
1 paź 2019 · Patients receiving vitamin K antagonist therapy should be treated using a systematic process to optimize effectiveness and minimize adverse effects.
10 lip 2023 · Objectives: Identify the mechanism of action of vitamin K. Describe the contraindications of vitamin K. Explain the importance of vitamin K concerning monitoring for patients on warfarin therapy, including target INR levels.
16 mar 2023 · Vitamin K antagonists (VKA) are a class of drugs used for therapeutic anticoagulation. The pharmacology and use of these drugs is discussed in separate topic reviews.
Strong recommendations include targeting an international normalized ratio of 2.0 to 3.0 for patients on vitamin K antagonist therapy (Grade 1B) and not routinely using pharmacogenetic testing for guiding doses of vitamin K antagonist (Grade 1B).
Among the key recommendations in this article are the following: for dosing of VKAs, we suggest the initiation of oral anticoagulation therapy with doses between 5 and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 2B).
8 mar 2019 · Patients receiving vitamin K antagonists (VKAs) with an international normalized ratio (INR) between 4.5 and 10 are at increased risk of bleeding. We systematically reviewed the literature to evaluate the effectiveness and safety of administering vitamin K in patients receiving VKA therapy with INR between 4.5 and 10 and without bleeding.
In patients beginning vitamin K antagonist (VKA) therapy, we recommend the initiation of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most individuals, with subsequent dosing based on the international normalized ratio (INR) response (Grade 1B).
